L. B. Nabors, J. Portnow, and M. Ammirati, Central nervous system cancers, version 2, J Natl Compr Canc Netw, vol.12, pp.1517-1523, 2014.

A. Kumari, S. S. Simon, and T. D. Moody, Immunomodulatory effects of radiation: what is next for cancer therapy?, Future Oncol, vol.12, pp.239-256, 2016.

Z. A. Kohutek, Y. Yamada, and T. A. Chan, Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases, J Neurooncol, vol.125, pp.149-156, 2015.

E. J. Chung, A. P. Brown, and H. Asano, In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase, Clin Cancer Res, vol.15, pp.3050-3057, 2009.

M. J. Sambade, E. C. Peters, and N. E. Thomas, Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032, Radiother Oncol, vol.98, pp.394-399, 2011.

C. J. Anker, A. Ribas, and A. H. Grossmann, Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma, J Clin Oncol, vol.31, pp.283-287, 2013.

J. J. Harding, C. A. Barker, and R. D. Carvajal, Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy, J Clin Oncol, vol.32, pp.54-56, 2014.

M. Hecht, L. Zimmer, and C. Loquai, Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients, Ann Oncol, vol.26, pp.1238-1244, 2015.

N. Lang, F. Sterzing, and A. H. Enk, Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia, Strahlenther Onkol, vol.190, pp.1080-1081, 2014.

L. Peuvrel, A. L. Ruellan, and F. Thillays, Severe radiotherapy-induced extracutaneous toxicity under vemurafenib, Eur J Dermatol, vol.23, pp.879-881, 2013.

M. Reigneau, F. Granel-brocard, and L. Geoffrois, Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?, Eur J Dermatol, vol.23, pp.544-545, 2013.

I. Satzger, A. Degen, and H. Asper, Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy, J Clin Oncol, vol.31, pp.220-222, 2013.

B. Schulze, M. Meissner, and M. Wolter, Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib, Strahlenther Onkol, vol.190, pp.229-232, 2014.

A. Forschner, D. Zips, and C. Schraml, Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib, Melanoma Res, vol.24, pp.512-516, 2014.

A. Narayana, M. Mathew, and M. Tam, Vemurafenib and radiation therapy in melanoma brain metastases, J Neurooncol, vol.113, pp.411-416, 2013.

N. Rompoti, B. Schilling, and E. Livingstone, Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity, J Clin Oncol, vol.31, pp.3844-3845, 2013.

K. A. Ahmed, J. M. Freilich, and S. Sloot, LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases, J Neurooncol, vol.122, pp.121-126, 2015.

D. A. Liebner, S. A. Walston, and R. Cavaliere, Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib, Melanoma Res, vol.24, pp.172-176, 2014.

K. R. Patel, M. Chowdhary, and J. M. Switchenko, BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis, Melanoma Res, vol.26, pp.387-394, 2016.

C. Gaudy-marqueste, R. Carron, and C. Delsanti, On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases, Ann Oncol, vol.25, pp.2086-2091, 2014.

Z. Xu, C. C. Lee, and R. A. , BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases, J Neurosurg, vol.126, pp.726-734, 2017.

D. Ly, H. P. Bagshaw, and C. J. Anker, Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment, J Neurosurg, vol.123, pp.395-401, 2015.

A. Wolf, S. Zia, and R. Verma, Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases, J Neurooncol, vol.127, pp.607-615, 2016.

B. G. Patel, K. A. Ahmed, and P. A. Johnstone, Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases, Melanoma Res, vol.26, pp.382-386, 2016.

T. Akimoto, N. R. Hunter, and L. Buchmiller, Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas, Clin Cancer Res, vol.5, pp.2884-2890, 1999.

P. Dent, D. B. Reardon, and J. S. Park, Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death, Mol Biol Cell, vol.10, pp.2493-2506, 1999.

R. K. Schmidt-ullrich, R. B. Mikkelsen, and P. Dent, Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation, Oncogene, vol.15, pp.1191-1197, 1997.

Y. Cai, J. Y. Wang, and H. Liu, Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure, Asian Pac J Cancer Prev, vol.14, pp.5699-5703, 2013.

Y. Fan, Z. Huang, and L. Fang, A phase II study of icotinib and wholebrain radiotherapy in Chinese patients with brain metastases from nonsmall cell lung cancer, Cancer Chemother Pharmacol, vol.76, pp.517-523, 2015.

Y. J. Huang, S. F. Liu, and C. J. Wang, Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer, Lung Cancer, vol.59, pp.407-410, 2008.

H. J. Kim, W. S. Kim, and D. H. Kwon, Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for brain metastases originating from non-small-cell lung cancer, J Korean Neurosurg Soc, vol.58, pp.205-210, 2015.

S. M. Lee, C. R. Lewanski, and N. Counsell, Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases, J Natl Cancer Inst, vol.106, 2014.

J. S. Lind, F. J. Lagerwaard, and E. F. Smit, Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from nonsmall-cell lung cancer, Int J Radiat Oncol Biol Phys, vol.74, pp.1391-1396, 2009.

Y. Lu and Y. Fan, Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis, Onco Targets Ther, vol.9, pp.1135-1143, 2016.

S. Ma, Y. Xu, and Q. Deng, Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population, Lung Cancer, vol.65, pp.198-203, 2009.

I. Olmez, B. R. Donahue, and J. S. Butler, Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis, Lung Cancer, vol.70, pp.174-179, 2010.

G. A. Pesce, D. Klingbiel, and K. Ribi, Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03), Eur J Cancer, vol.48, pp.377-384, 2012.

P. W. Sperduto, M. Wang, and H. I. Robins, A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320, Int J Radiat Oncol Biol Phys, vol.85, pp.1312-1318, 2013.

F. Wang, F. Ning, and C. Liu, Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from nonsmall cell lung cancer, Cell Biochem Biophys, vol.71, pp.1261-1265, 2015.

J. W. Welsh, R. Komaki, and A. Amini, Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer, J Clin Oncol, vol.31, pp.895-902, 2013.

Y. D. Zeng, L. Zhang, and H. Liao, Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from nonsmall-cell lung cancer: a retrospective study, Asian Pac J Cancer Prev, vol.13, pp.909-914, 2012.

Y. D. Zeng, H. Liao, and T. Qin, Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy, Oncotarget, vol.6, pp.8366-8376, 2015.

H. Zhuang, Z. Yuan, and J. Wang, Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma, Drug Des Devel Ther, vol.7, pp.1179-1186, 2013.

L. Zhou, J. Liu, and J. Xue, Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer, Radiat Oncol, vol.9, p.117, 2014.

L. Zhou, J. He, and W. Xiong, Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study, Lung Cancer, vol.96, pp.93-100, 2016.

T. Jiang, W. Min, and Y. Li, Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis, Cancer Med, vol.5, pp.1055-1065, 2016.

S. Luo, L. Chen, and X. Chen, Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases, Oncotarget, vol.6, pp.16725-16734, 2015.

Q. Zhu, Y. Sun, and Y. Cui, Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC), Oncotarget, vol.8, pp.13304-13311, 2017.

Z. Deng, H. Huang, and X. Wu, Distinct expression of various angiogenesis factors in mice brain after whole-brain irradiation by X-ray, Neurochem Res, vol.42, pp.625-633, 2017.

S. Vala, I. Martins, L. R. Imaizumi, and N. , Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis, PLoS One, vol.5, p.11222, 2010.

D. Zingg, O. Riesterer, and D. Fabbro, Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells, Cancer Res, vol.64, pp.5398-5406, 2004.

J. E. Bates, P. Youn, C. R. Peterson, and . Iii, Radiotherapy for brain metastases from renal cell carcinoma in the targeted therapy era: The University of Rochester Experience, Am J Clin Oncol, 2015.

D. C. Cochran, M. D. Chan, and M. Aklilu, The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery, J Neurosurg, vol.116, pp.978-983, 2012.

M. Staehler, N. Haseke, and P. Nuhn, Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma, BJU Int, vol.108, pp.673-678, 2011.

M. Staehler, N. Haseke, and T. Stadler, Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer, Urol Oncol, vol.30, issue.3, p.290, 2012.

J. Verma, E. Jonasch, and P. K. Allen, The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma, Am J Clin Oncol, vol.36, pp.620-624, 2013.

J. Langrand-escure, A. Vallard, and R. Rivoirard, Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report, Anticancer Drugs, vol.27, pp.427-432, 2016.

E. J. Wuthrick, M. Kamrava, W. J. Curran, and J. , A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies, Cancer, vol.117, pp.5548-5559, 2011.

F. Winkler, S. V. Kozin, and R. T. Tong, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases, Cancer Cell, vol.6, pp.553-563, 2004.

R. P. Dings, M. Loren, and H. Heun, Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization, Clin Cancer Res, vol.13, pp.3395-3402, 2007.

R. Masood, J. Cai, and T. Zheng, Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors, Blood, vol.98, pp.1904-1913, 2001.

J. P. Truman, M. Garcia-barros, and M. Kaag, Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery, PLoS One, vol.5, 2010.

P. Fu, Y. S. He, and Q. Huang, Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials, Mol Clin Oncol, vol.4, pp.833-838, 2016.

O. L. Chinot, R. Nishikawa, and W. Mason, Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio, Neuro Oncol, vol.18, pp.1313-1318, 2016.

C. Levy, D. Allouache, and J. Lacroix, REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours, Ann Oncol, vol.25, pp.2351-2356, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02939568

C. Chargari, H. R. Idrissi, and J. Y. Pierga, Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients, Int J Radiat Oncol Biol Phys, vol.81, pp.631-636, 2011.

H. J. Stemmler, M. Schmitt, and A. Willems, Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier, Anticancer Drugs, vol.18, pp.23-28, 2007.

N. U. Lin, R. A. Freedman, and N. Ramakrishna, A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases, Breast Cancer Res Treat, vol.142, pp.405-414, 2013.

S. Yomo, M. Hayashi, and N. Cho, Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer, J Neurooncol, vol.112, pp.199-207, 2013.

G. S. Borges, R. K. Rovere, and S. M. Dias, Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature, Ecancermedicalscience, vol.9, p.586, 2015.

W. Jacot, E. Pons, and J. S. Frenel, Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases, Breast Cancer Res Treat, vol.157, pp.307-318, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02296735

J. A. Carlson, Z. Nooruddin, and C. Rusthoven, Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema, Neuro Oncol, vol.16, pp.1006-1009, 2014.

A. Geraud, H. P. Xu, and P. Beuzeboc, Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer, J Neurooncol, vol.131, pp.69-72, 2017.

K. Mitsuya, J. Watanabe, and Y. Nakasu, Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases, BMC Cancer, vol.16, p.391, 2016.

J. E. Shabason and A. J. Minn, Radiation and immune checkpoint blockade: from bench to clinic, Semin Radiat Oncol, vol.27, pp.289-298, 2017.

M. Z. Dewan, A. E. Galloway, and N. Kawashima, Fractionated but not singledose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody, Clin Cancer Res, vol.15, pp.5379-5388, 2009.

S. C. Formenti and S. Demaria, Combining radiotherapy and cancer immunotherapy: a paradigm shift, J Natl Cancer Inst, vol.105, pp.256-265, 2013.

A. Kalbasi, C. H. June, and N. Haas, Radiation and immunotherapy: a synergistic combination, J Clin Invest, vol.123, pp.2756-2763, 2013.

R. E. Vatner, B. T. Cooper, and C. Vanpouille-box, Combinations of immunotherapy and radiation in cancer therapy, Front Oncol, vol.4, p.325, 2014.

F. Dhermain and E. Deutsch, Stereotactic radiation and checkpoint inhibitors in melanoma patients with BM: a question of drug, timing or both?, Ann Oncol, vol.27, pp.371-372, 2016.

S. Du-four, S. Wilgenhof, and J. Duerinck, Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies, Eur J Cancer, vol.48, pp.3045-3051, 2012.

A. P. Kiess, J. D. Wolchok, and C. A. Barker, Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment, Int J Radiat Oncol Biol Phys, vol.92, pp.368-375, 2015.

J. P. Knisely, J. B. Yu, and J. Flanigan, Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival, J Neurosurg, vol.117, pp.227-233, 2012.

M. Mathew, M. Tam, and P. A. Ott, Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery, Melanoma Res, vol.23, pp.191-195, 2013.

K. R. Patel, S. Shoukat, and D. E. Oliver, Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases, Am J Clin Oncol, 2015.

A. W. Silk, M. F. Bassetti, and B. T. West, Ipilimumab and radiation therapy for melanoma brain metastases, Cancer Med, vol.2, pp.899-906, 2013.

K. Tazi, A. Hathaway, and C. Chiuzan, Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery, Cancer Med, vol.4, pp.1-6, 2015.

N. K. Gerber, R. J. Young, and C. A. Barker, Ipilimumab and whole brain radiation therapy for melanoma brain metastases, J Neurooncol, vol.121, pp.159-165, 2015.

O. Cohen-inbar, H. H. Shih, and Z. Xu, The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab, J Neurosurg, vol.127, pp.1007-1014, 2017.

K. A. Ahmed, D. G. Stallworth, and Y. Kim, Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy, Ann Oncol, vol.27, pp.434-441, 2016.

A. K. Alomari, J. Cohen, and A. O. Vortmeyer, Possible interaction of anti-PD-1 therapy with the effects of radiosurgery on brain metastases, Cancer Immunol Res, vol.4, pp.481-487, 2016.

J. M. Qian, J. B. Yu, and H. M. Kluger, Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery, Cancer, vol.122, pp.3051-3058, 2016.

N. U. Lin, E. Q. Lee, and H. Aoyama, Response assessment criteria for brain metastases: proposal from the RANO group, Lancet Oncol, vol.16, pp.270-278, 2015.